Literature DB >> 23669129

Medical outcomes associated with nonmedical use of methadone and buprenorphine.

Samantha Lee1, Wendy Klein-Schwartz, Christopher Welsh, Suzanne Doyon.   

Abstract

BACKGROUND: There exists a significant amount of misinformation regarding methadone and buprenorphine, and a belief that toxicity associated with nonmedical use of methadone and nonmedical use of buprenorphine is similar in severity and outcomes.
OBJECTIVE: The objective of this study is to compare outcomes associated with nonmedical use of methadone vs. nonmedical use of buprenorphine in patients presenting to the Emergency Department (ED) and reported to poison centers.
METHODS: This was a retrospective cohort study using data from the American Association of Poison Control Centers from January 1, 2003 to December 31, 2009 (7 years). Inclusion criteria were nonmedical use of methadone or buprenorphine (or buprenorphine/naloxone) as a single substance by history, age 18 years or older, ingestions only, evaluated in an ED. Outcome measures were clinical effects, treatments, disposition, and final medical outcomes.
RESULTS: Of 1,920 cases, 1,594 were in the methadone group and 326 were in the buprenorphine group. Frequently reported clinical effects were lethargy, 59.2% vs. 29.4%, and respiratory depression, 28.7% vs. 2.5%, for methadone and buprenorphine groups, respectively. Hospitalization rates were 67.4% in the methadone group and 32.2% in the buprenorphine group. Half of all patients in the methadone group were admitted to the intensive care unit (ICU) vs. only 15% of all the patients in the buprenorphine group. Twenty-six patients in the methadone group died vs. no deaths in the buprenorphine group. There were significant differences in the distribution of clinical effects, disposition, and medical outcomes (p < 0.001).
CONCLUSIONS: Patients who use methadone nonmedically have higher hospitalization rates, greater ICU utilization rates, and considerably worse medical outcomes when compared with patients who use buprenorphine nonmedically.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  buprenorphine; methadone; nonmedical use

Mesh:

Substances:

Year:  2013        PMID: 23669129     DOI: 10.1016/j.jemermed.2012.11.104

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  10 in total

1.  ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder.

Authors:  Ryan Marino; Jeanmarie Perrone; Lewis S Nelson; Timothy J Wiegand; Evan S Schwarz; Paul M Wax; Andrew I Stolbach
Journal:  J Med Toxicol       Date:  2019-08-14

Review 2.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

3.  A comparison of opioid-involved fatalities captured in the National Poison Data System to data derived from US death certificate literal text.

Authors:  Celeste A Mallama; James P Trinidad; Richard S Swain; Yueqin Zhao; Corinne Woods; Jana K McAninch
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-08-11       Impact factor: 2.890

Review 4.  Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?

Authors:  Anita Srivastava; Meldon Kahan; Maya Nader
Journal:  Can Fam Physician       Date:  2017-03       Impact factor: 3.275

5.  A case report of methadone-associated hypoglycemia in an 11-month-old male.

Authors:  Michael S Toce; Margaret A Stefater; David T Breault; Michele M Burns
Journal:  Clin Toxicol (Phila)       Date:  2017-06-26       Impact factor: 4.467

6.  Prior Experience with Non-Prescribed Buprenorphine: Role in Treatment Entry and Retention.

Authors:  Laura B Monico; Shannon Gwin Mitchell; Jan Gryczynski; Robert P Schwartz; Kevin E O'Grady; Yngvild K Olsen; Jerome H Jaffe
Journal:  J Subst Abuse Treat       Date:  2015-05-07

7.  Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?

Authors:  Molly Doernberg; Noa Krawczyk; Deborah Agus; Michael Fingerhood
Journal:  Subst Abus       Date:  2019-04-22       Impact factor: 3.716

Review 8.  Buprenorphine Prescribing: To Expand or Not to Expand.

Authors:  Xiaofan Li; Daryl Shorter; Thomas R Kosten
Journal:  J Psychiatr Pract       Date:  2016-05       Impact factor: 1.325

Review 9. 

Authors:  Anita Srivastava; Meldon Kahan; Maya Nader
Journal:  Can Fam Physician       Date:  2017-03       Impact factor: 3.275

10.  Opioid Overdose Deaths with Buprenorphine Detected in Postmortem Toxicology: a Retrospective Analysis.

Authors:  Rachel S Wightman; Jeanmarie Perrone; Rachel Scagos; Maxwell Krieger; Lewis S Nelson; Brandon D L Marshall
Journal:  J Med Toxicol       Date:  2020-07-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.